Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-222
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
bim
Cancer name
Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Doxorubicin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Up
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-222 could function as an oncogene and was able to reduce the sensitivity of breast cancer cells to DOX through miR-222-Bim-caspase pathway, which provided a potential target to increase DOX sensitivity in clinical breast cancer treatmen.
Tissue resource
blood samples from healthy subjects and breast cancer patients
breast cancer cell line MCF-7
breast cancer doxorubicin-resistant cell lines MCF-7-R
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
the Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University
the Shanghai Gaining Biotechnology Co., Ltd.
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.